Valeant Pharmaceuticals International Inc aims to crack the top-five ranks of drug companies by market capitalization by the end of 2016, Chief Executive Michael Pearson said on Tuesday. Montreal, Quebec-based Valeant, which has a market cap of about $38.4 billion and sits among the top 15 pharmaceutical companies by that measure, would need to reach about $150 billion in market cap to crack the top five, Pearson said on a call with analysts and investors.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX remained unchanged at $112.62. In the past year, the shares have traded as low as $61.10 and as high as $118.25. On average, 1082480 shares of VRX exchange hands on a given day and today's volume is recorded at 380.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 3.72% or $-4.63/share to $119.99. In the past year, the shares have traded as low as $60.29 and as high as $125.71. On average, 358895 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 462255.
Source
